Form 8-K - Current report:
SEC Accession No. 0000950170-23-046715
Filing Date
2023-09-06
Accepted
2023-09-06 16:05:02
Documents
12
Period of Report
2023-09-06
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K ubx-20230906.htm   iXBRL 8-K 52241
  Complete submission text file 0000950170-23-046715.txt   170063

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ubx-20230906.xsd EX-101.SCH 2484
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ubx-20230906_lab.xml EX-101.LAB 13350
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ubx-20230906_pre.xml EX-101.PRE 9851
6 EXTRACTED XBRL INSTANCE DOCUMENT ubx-20230906_htm.xml XML 4715
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

EIN.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38470 | Film No.: 231239134
SIC: 2834 Pharmaceutical Preparations